Summary: Due to the influx of COVID-19 related therapies being expedited into clinical testing, studies in other areas are either proceeding with heightened caution or are essentially being...

Summary: Catalent and Fierce Pharma surveyed 234 individuals involved in clinical supply and clinical operations to better understand the industry perception around importance of having a direct-to-patient option...

Summary: Proactive clinical supply risk evaluation and tailored strategies to support on-time study start-up for small and mid-sized sponsors...

Summary: The Asia-Pacific (APAC) region has become an emerging market for pharmaceutical and biotech innovation, including clinical studies. Managing a clinical supply distribution strategy within APAC...

Summary: After 3 years of Brexit withdrawal negotiations, the UK is officially no longer a member of the European Union. Clinical sponsors with active and planned studies in the EU...

Summary: Overcoming complex blinding and masking challenges in clinical trials requires a balance of strategy and adaptability. When conducting clinical trials...

Summary: With the growth in semi and fully remote clinical studies, the ability to offer direct-to-patient distribution of clinical supplies is becoming increasingly important for clinical...

Summary: With an increasing number of clinical studies being conducted in the Asia-Pacific (APAC) region, there is a growing need for streamlining import and export strategies...

Ensuring an adequate, timely, and quality supply of comparator product for clinical trials is critical, but clinical trial sponsors face several challenges in this endeavor.

Ensuring an adequate, timely, and quality supply of comparator product for clinical trials is critical, but clinical trial sponsors face several challenges in this endeavor.